On November 17, 2015 Chugai Pharmaceutical Co., Ltd. (Chugai) (TOKYO: 4519) reported that regarding an application for patent term extension based on a market approval with respect to one of the regimens (i.e. 7.5 mg/kg every 3 weeks or more) in colorectal cancer, which has been disputed between Genentech Inc. (Genentech), a member of the Roche group, and Japan Patent Office (JPO), the Supreme Court decided to maintain the Intellectual Property High Court Grand Panel’s case decision that the trial decision of JPO to deny the application for patent term extension should be revoked (Press release, Chugai, NOV 17, 2015, View Source [SID:1234508259]).
The examination whether the patent term extension is acceptable or not will be proceeded again by JPO in light of this decision.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Genentech is a patent holder and Chugai is the licensee of Avastin.

Chugai will continue to promote the proper use of Avastin.

The impact of the matter on our financial results is currently under scrutiny. Should any information necessary to be disclosed becomes clear in the future, it will be promptly disclosed.